Phase 19/2 Studies of Covid 3 Antibody Therapy Started

Phase 19/2 Studies of Covid-3 Antibody Therapy Started
Phase 19/2 Studies of Covid-3 Antibody Therapy Started

Regarding the antibody treatment, whose studies were initiated to prevent hospitalization due to Covid-19, with the statement made by the two companies, it was announced that Phase 2/3 clinical trials where the safety and efficacy of the treatment were evaluated.


It was announced that if the first results to be presented before the end of 2020 are positive, early access to antibody therapy in the first half of 2021 will be possible.

GSK and Vir Biotechnology announced that the dose was administered to the first patient as part of the Phase 19/2 study for the early treatment of COVID-3 in patients at high risk of hospitalization.

The PHASE 1.300/2 study, which included approximately 3 patients with early symptomatic infections worldwide, is conducted to assess whether a single dose of monoclonal antibody (VIR-7831) will prevent hospitalization for COVID-19. In the study, which is aimed to get the first results before the end of this year, if the results are successful, it will be possible to access antibody therapy early in the first half of 2021.

GSK's Head of R&D and Scientific Officer Dr. "Monoclonal antibodies against the SARS-CoV-2 virus can provide an effective and immediate immune response to COVID-19 without waiting for our body to produce its own antibodies," Hal Barron said in a statement. I think this is particularly important in the absence of an effective vaccine. This study will evaluate the ability of VIR-7831 to prevent high-risk individuals from progressing to severe disease. "In future studies, we will also test the rate at which the antibody can prevent infection and reduce disease severity in high-risk patients."

Vir CEO Ph.D. George Scangos said: “It is very important for both patients and society to treat patients with onset of COVID-19 in a way that prevents them from getting worse. Hospital systems around the world have failed, with new infections that continue to strain resources that are currently limited. This study was designed to show whether VIR-7831 could significantly reduce the need for hospitalization in the elderly or high-risk individuals with chronic conditions. said.

Hibya News Agency



conversation

Be the first to comment

Comments